Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
| dc.contributor.author | Mikasi, Sello G. | en_ZA |
| dc.contributor.author | Isaacs, Darren | en_ZA |
| dc.contributor.author | Chitongo, Rumbidzai | en_ZA |
| dc.contributor.author | Ikomey, George M. | en_ZA |
| dc.contributor.author | Jacobs, Graeme B. | en_ZA |
| dc.contributor.author | Cloete, Ruben | en_ZA |
| dc.date.accessioned | 2021-04-29T10:19:45Z | |
| dc.date.available | 2021-04-29T10:19:45Z | |
| dc.date.issued | 2021-04-23 | |
| dc.date.updated | 2021-04-25T04:21:52Z | |
| dc.description | CITATION: Mikasi, S. G., et al. 2021. Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations. BMC Infectious Diseases, 21:379, doi:10.1186/s12879-021-06059-x. | |
| dc.description | The original publication is available at https://bmcinfectdis.biomedcentral.com | |
| dc.description.abstract | Background: The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). DTG containing regimens have shown a high genetic barrier against HIV-1 isolates carrying specific resistance mutations when compared with other class of regimens. Methods: We evaluated the HIV-1 CRF02_AG IN gene sequences from Cameroon for the presence of resistanceassociated mutations (RAMs) against INSTIs and naturally occurring polymorphisms (NOPs), using study sequences (n = 20) and (n = 287) sequences data derived from HIV Los Alamos National Laboratory database. The possible impact of NOPs on protein structure caused by HIV-1 CRF02_AG variations was addressed within the context of a 3D model of the HIV-1 IN complex and interaction analysis was performed using PyMol to validate DTG binding to the Wild type and seven mutant structures. Results: We observed 12.8% (37/287) sequences to contain RAMs, with only 1.0% (3/287) of the sequences having major INSTI RAMs: T66A, Q148H, R263K and N155H. Of these,11.8% (34/287) of the sequences contained five different IN accessory mutations; namely Q95K, T97A, G149A, E157Q and D232N. NOPs occurred at a frequency of 66% on the central core domain (CCD) position, 44% on the C-terminal domain (CTD) position and 35% of the Nterminal domain (NTD) position. The interaction analysis revealed that DTG bound to DNA, 2MG ions and DDE motif residues for T66A, T97A, Q148H, N155H and R263K comparable to the WT structure. Except for accessory mutant structure E157Q, only one MG contact was made with DTG, while DTG had no MG ion contacts and no DDE motif residue contacts for structure D232N. Conclusions: Our analysis indicated that all RAM’s that resulted in a change in the number of interactions with encompassing residues does not affect DTG binding, while accessory mutations E157Q and D232N could affect DTG binding leading to possible DTG resistance. However, further experimental validation is required to validate the in silico findings of our study. | |
| dc.description.uri | https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06059-x | |
| dc.description.version | Publisher's version | |
| dc.format.extent | 12 pages | en_ZA |
| dc.identifier.citation | Mikasi, S. G., et al. 2021. Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations. BMC Infectious Diseases, 21:379, doi:10.1186/s12879-021-06059-x | |
| dc.identifier.issn | 1471-2334 (online) | |
| dc.identifier.other | doi:10.1186/s12879-021-06059-x | |
| dc.identifier.uri | http://hdl.handle.net/10019.1/110363 | |
| dc.language.iso | en_ZA | en_ZA |
| dc.publisher | BMC (part of Springer Nature) | en_ZA |
| dc.rights.holder | Authors retain copyright | en_ZA |
| dc.subject | Inhibitors | en_ZA |
| dc.subject | Strand transfer inhibitor | en_ZA |
| dc.subject | Dolutegravir | en_ZA |
| dc.subject | Drug resistance -- Mutation (Biology) | en_ZA |
| dc.subject | Recombinant protease inhibitors | en_ZA |
| dc.title | Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations | en_ZA |
| dc.type | Article | en_ZA |